OCUL Ocular Therapeutix, Inc.
$10.49▼ -1.22%
Healthcare
Other
After hours
$10.69▲ +1.91%
Sep 11, 7:44 PM ET
Volume 2.63M
Avg Volume (10D) 1.95M
Key Metrics & Fundamentals
Market Cap
$2.30B
P/E Ratio
–
Div Yield
–%
52W Range
6.23 - 16.44
% vs 50 MA
6.41%
% vs 200 MA
5.65%
RSI-14
50.6
MACD Histogram
-0.0600
Beta (1Y vs SPY)
1.00
Free Cash Flow
-$70.64M
Gross Rev
$13.48M
Gross Profit
$11.46M
EBITDA
-$74.81M
COGS
$2.01M
Operating Exp
$93.57M
Operating Income
-$82.11M
EBIT
-$82.11M
Pretax Income
-$78.76M
Net Income
-$78.76M
EPS (Diluted)
-0.35
Price & Volume History
Loading chart…
Recent News
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
Insider Monkey · Sep 3, 2026 11:06 AM
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
GlobeNewswire · Sep 1, 2026 11:00 AM
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
StockStory · Sep 1, 2026 10:10 AM
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
Simply Wall St. · Aug 22, 2026 2:08 PM
Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress
Simply Wall St. · Aug 22, 2026 6:10 AM
Ocular Therapeutix (OCUL) Stock Fair Value Edges Higher After Analyst Target Increases
Simply Wall St. · Aug 22, 2026 1:12 AM
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
StockStory · Aug 21, 2026 7:47 PM
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why
Stocktwits · Aug 17, 2026 11:51 PM
EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate
Stocktwits · Aug 17, 2026 1:19 PM
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 13, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See OCUL's money flow as a full page
Social Sentiment
No Reddit posts found for OCUL.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.